MX2010013265A - Anticuerpos anti-cd8 bloquean cebado de efectores citotoxicos y conducen a generacion de celulas t cd8+ reguladoras. - Google Patents

Anticuerpos anti-cd8 bloquean cebado de efectores citotoxicos y conducen a generacion de celulas t cd8+ reguladoras.

Info

Publication number
MX2010013265A
MX2010013265A MX2010013265A MX2010013265A MX2010013265A MX 2010013265 A MX2010013265 A MX 2010013265A MX 2010013265 A MX2010013265 A MX 2010013265A MX 2010013265 A MX2010013265 A MX 2010013265A MX 2010013265 A MX2010013265 A MX 2010013265A
Authority
MX
Mexico
Prior art keywords
cells
antibody
conformance
reiv
suppressor
Prior art date
Application number
MX2010013265A
Other languages
English (en)
Spanish (es)
Inventor
Jacques F Banchereau
Eynav Klechevsky
Anna Karolina Palucka
Original Assignee
Baylor Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Inst filed Critical Baylor Res Inst
Publication of MX2010013265A publication Critical patent/MX2010013265A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/505—CD4; CD8

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2010013265A 2008-06-06 2009-06-05 Anticuerpos anti-cd8 bloquean cebado de efectores citotoxicos y conducen a generacion de celulas t cd8+ reguladoras. MX2010013265A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5964708P 2008-06-06 2008-06-06
PCT/US2009/046464 WO2009149382A2 (en) 2008-06-06 2009-06-05 Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+t cells

Publications (1)

Publication Number Publication Date
MX2010013265A true MX2010013265A (es) 2011-02-24

Family

ID=41398905

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010013265A MX2010013265A (es) 2008-06-06 2009-06-05 Anticuerpos anti-cd8 bloquean cebado de efectores citotoxicos y conducen a generacion de celulas t cd8+ reguladoras.

Country Status (14)

Country Link
US (1) US20090304659A1 (enExample)
EP (1) EP2297204A4 (enExample)
JP (1) JP2011522835A (enExample)
KR (1) KR20110025812A (enExample)
CN (1) CN102112491A (enExample)
AU (1) AU2009255999A1 (enExample)
BR (1) BRPI0915582A2 (enExample)
CA (1) CA2728772A1 (enExample)
IL (1) IL209798A0 (enExample)
MX (1) MX2010013265A (enExample)
NZ (1) NZ590197A (enExample)
TW (1) TW201000130A (enExample)
WO (1) WO2009149382A2 (enExample)
ZA (1) ZA201100061B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5825966B2 (ja) * 2011-10-11 2015-12-02 株式会社日本バイオセラピー研究所 Ｃｄ５６陽性ｔ細胞増強方法
US10092597B2 (en) 2014-01-14 2018-10-09 The University Of Hong Kong Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice
WO2018085897A1 (en) * 2016-11-14 2018-05-17 Murdoch Childrens Research Institute Transplant rejection assay
KR102880156B1 (ko) * 2017-07-24 2025-11-05 리제너론 파마슈티칼스 인코포레이티드 항cd8 항체 및 이의 용도
US20220227887A1 (en) 2019-06-11 2022-07-21 Ono Pharmaceutical Co., Ltd. Immunosuppressant
US20240209089A1 (en) * 2020-07-21 2024-06-27 Suzhou Smartnuclide Biopharmaceutical Co., Ltd. Cd8 binding polypeptide and use thereof
CN112156110B (zh) * 2020-09-15 2022-10-14 上海交通大学医学院 Cd8+抑制性t细胞在免疫调节中的应用及诱导方法
EP4340866A4 (en) 2021-05-19 2025-05-21 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
CN120569191A (zh) 2022-11-23 2025-08-29 乔治亚大学研究基金公司 用于增加免疫应答的组合物及其使用方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178858A (en) * 1987-12-02 1993-01-12 Reichert Thomas A Method for prevention of graft versus host disease
CA1339840C (en) * 1988-12-16 1998-04-28 Kenneth Kortright Method and apparatus for screening cells or formed bodies with populations expressing selected characteristics
US5601828A (en) * 1989-03-15 1997-02-11 Tkb Associates Limited Partnership CD8 derivatives and methods of use for cellular modulation and enhancement of cellular engraftment
GB8912497D0 (en) * 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
CA2096530A1 (en) * 1990-11-23 1992-05-24 Thomas Russell Method and apparatus for screening microscopic cells utilizing light scatter techniques
US5876708A (en) * 1992-02-19 1999-03-02 The General Hospital Corporation Allogeneic and xenogeneic transplantation
US6911220B1 (en) * 1992-02-19 2005-06-28 The General Hospital Corporation Allogeneic and xenogeneic transplantation
US6335174B1 (en) * 1996-04-05 2002-01-01 South Alabama Medical Science Foundation Oncofetal antigen specific t-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10
JP2001511187A (ja) * 1997-02-28 2001-08-07 エンゾー セラピュウティクス， インコーポレイテッド 選択的免疫ダウンレギュレーション（ｓｉｄｒ）を行う新規プロセス
US6803036B1 (en) * 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
US20040022761A1 (en) * 2001-05-11 2004-02-05 Banchereau Jacques F Compositions and methods for producing antigen-presenting cells
JP4344696B2 (ja) * 2002-09-27 2009-10-14 バイオイー， インコーポレイテッド 細胞分離組成物および細胞分離法
CA2522380A1 (en) * 2003-03-19 2004-09-30 Isogenis, Inc. Specific inhibition of allorejection
GB0314461D0 (en) * 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
EP1674479A1 (en) * 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulation of Fc Gamma receptors for optimizing immunotherapy
WO2008005859A2 (en) * 2006-06-30 2008-01-10 Baylor Research Institute Dendritic cells generated using gm-csf and interferon alpha and loaded with heat-treated and killed cancer cells

Also Published As

Publication number Publication date
CN102112491A (zh) 2011-06-29
JP2011522835A (ja) 2011-08-04
WO2009149382A3 (en) 2010-04-29
NZ590197A (en) 2012-10-26
TW201000130A (en) 2010-01-01
AU2009255999A1 (en) 2009-12-10
BRPI0915582A2 (pt) 2016-01-26
EP2297204A4 (en) 2013-10-23
CA2728772A1 (en) 2009-12-10
US20090304659A1 (en) 2009-12-10
EP2297204A2 (en) 2011-03-23
KR20110025812A (ko) 2011-03-11
WO2009149382A2 (en) 2009-12-10
IL209798A0 (en) 2011-02-28
ZA201100061B (en) 2011-10-26

Similar Documents

Publication Publication Date Title
US10577586B2 (en) Compositions and methods for modulating an immune response
Zhou et al. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia
MX2010013265A (es) Anticuerpos anti-cd8 bloquean cebado de efectores citotoxicos y conducen a generacion de celulas t cd8+ reguladoras.
TWI841576B (zh) 用於治療傳染病之共受體系統
CN109069539A (zh) 用于癌症治疗的联合免疫疗法和细胞因子控制疗法
Teitz-Tennenbaum et al. Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy
CN1981031A (zh) 调节性t细胞及它们在免疫治疗和抑制自身免疫反应中的应用
TW201247700A (en) Immunoglobulin-like transcript (ILT) receptors as CD8 antagonists
US20090232854A1 (en) Uses of bispecific antibody coated dendritic cells pulsed with antigens and gm-csf in immune regulation
US20250197498A1 (en) Methods for in vivo expansion of cd8+ t cells and prevention or treatment of gvhd
US12427181B2 (en) T-cell therapy method
Côté et al. Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens
Capitini et al. Graft-versus-host disease impairs vaccine responses through decreased CD4+ and CD8+ T cell proliferation and increased perforin-mediated CD8+ T cell apoptosis
US20150110738A1 (en) Methods and compositions for generating and using allogeneic suppressor cells
Dace et al. CD8+ T cells circumvent immune privilege in the eye and mediate intraocular tumor rejection by a TNF-α-dependent mechanism
Han et al. Antibody-suppressor CXCR5+ CD8+ T cells are more potent regulators of humoral alloimmunity after kidney transplant in mice compared to CD4+ regulatory T cells
Inoue et al. Host Foxp3+ CD4+ regulatory T cells act as a negative regulator of dendritic cells in the peritransplantation period
Ramírez et al. Impact of T cell selection methods in the success of clinical adoptive immunotherapy
Kalish A neutrophil-based approach to elicit natural killer cells into an immunologically" cold" tumor
Field Attenuation of Immune Suppression to Complement Glioma Immunotherapy
Sen Targeting Siglecs on Recipient Antigenpresenting Cells With Sialic Acid-Modified Alloantigen to Promote Transplantation Tolerance
Shen IL-12 CAR T cell Immunotherapy for Heterogeneous Brain Tumors
HK1155467A (en) Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+t cells
Alexander T regulatory cells and the germinal center
Lee Allogeneic Double Negative T cell Therapy as a Novel Treatment for AML Patients

Legal Events

Date Code Title Description
FG Grant or registration